DK3076969T3 - Doseringsregime for en alfa-isoform-selektiv phosphatidylinositol-3-kinase-hæmmer - Google Patents

Doseringsregime for en alfa-isoform-selektiv phosphatidylinositol-3-kinase-hæmmer Download PDF

Info

Publication number
DK3076969T3
DK3076969T3 DK14812658.4T DK14812658T DK3076969T3 DK 3076969 T3 DK3076969 T3 DK 3076969T3 DK 14812658 T DK14812658 T DK 14812658T DK 3076969 T3 DK3076969 T3 DK 3076969T3
Authority
DK
Denmark
Prior art keywords
isoform
alpha
kinase inhibitor
dosage regimen
selective phosphatidylinositol
Prior art date
Application number
DK14812658.4T
Other languages
English (en)
Inventor
Tomaso Emmanuelle Di
Ranjana Tavorath
Marie-Caroline Germa
Cristian Massacesi
Christine Fritsch
Christian Rene Schnell
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3076969T3 publication Critical patent/DK3076969T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK14812658.4T 2013-12-06 2014-12-03 Doseringsregime for en alfa-isoform-selektiv phosphatidylinositol-3-kinase-hæmmer DK3076969T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13306679 2013-12-06
PCT/IB2014/066558 WO2015083101A1 (en) 2013-12-06 2014-12-03 Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor

Publications (1)

Publication Number Publication Date
DK3076969T3 true DK3076969T3 (da) 2021-11-22

Family

ID=49876516

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14812658.4T DK3076969T3 (da) 2013-12-06 2014-12-03 Doseringsregime for en alfa-isoform-selektiv phosphatidylinositol-3-kinase-hæmmer

Country Status (23)

Country Link
US (4) US20170000778A1 (da)
EP (2) EP4000619A1 (da)
JP (1) JP2016539149A (da)
KR (1) KR20160095035A (da)
CN (1) CN105979947A (da)
AU (2) AU2014358773A1 (da)
BR (1) BR112016011811A2 (da)
CA (1) CA2930359C (da)
CL (1) CL2016001361A1 (da)
DK (1) DK3076969T3 (da)
ES (1) ES2899167T3 (da)
HK (1) HK1223549A1 (da)
HU (1) HUE057092T2 (da)
IL (1) IL245709B (da)
MX (1) MX2016007376A (da)
PH (1) PH12016501026A1 (da)
PL (1) PL3076969T3 (da)
PT (1) PT3076969T (da)
RU (1) RU2680246C1 (da)
SI (1) SI3076969T1 (da)
TN (1) TN2016000179A1 (da)
TW (1) TWI666019B (da)
WO (1) WO2015083101A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180073674A (ko) * 2015-11-02 2018-07-02 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제에 대한 투여 요법
WO2018060833A1 (en) * 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US4323581A (en) 1978-07-31 1982-04-06 Johnson & Johnson Method of treating carcinogenesis
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
WO1988007045A1 (en) 1987-03-09 1988-09-22 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance k-252
US4904768A (en) 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
WO1989007105A1 (en) 1988-02-04 1989-08-10 Kyowa Hakko Kogyo Co., Ltd. Staurosporin derivatives
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
AU2866992A (en) 1991-10-10 1993-05-03 Schering Corporation 4'-(n-substituted-n-oxide)staurosporine derivatives
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
CA2123096A1 (en) 1991-11-08 1993-05-13 Beat J. Knusel Compositions containing k-252 compounds for potentiation of neurotrophin activity
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5948898A (en) 1992-03-16 1999-09-07 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5756494A (en) 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
ATE280180T1 (de) 1992-08-31 2004-11-15 Ludwig Inst Cancer Res Vom mage-3-gen abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen
CA2123895A1 (en) 1992-09-21 1994-03-31 Tatsuya Tamaoki A therapeutic agent for thrombocytopenia
DK0666868T4 (da) 1992-10-28 2006-09-18 Genentech Inc Anvendelse af anti-VEGF-antistoffer til behandling af cancer
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
JPH09500128A (ja) 1993-07-15 1997-01-07 ミネソタ マイニング アンド マニュファクチャリング カンパニー イミダゾ〔４，５−ｃ〕ピリジン−４−アミン
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
ES2236702T3 (es) 1993-12-23 2005-07-16 Eli Lilly And Company Inhibidores de la proteina quinasa c.
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
EP1110953B1 (en) 1995-03-30 2009-10-28 Pfizer Products Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
WO1997007081A2 (en) 1995-08-11 1997-02-27 Yale University Glycosylated indolocarbazole synthesis
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
EP0865440B1 (en) 1995-12-08 2002-04-03 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
KR100447918B1 (ko) 1996-07-25 2005-09-28 동아제약주식회사 대장을포함한위장관보호작용을갖는플라본및플라바논화합물
AU738592C (en) 1996-08-02 2002-07-25 Lorus Therapeutics Inc. Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
EP1017394B1 (en) 1997-07-12 2005-12-07 Cancer Research Technology Limited Cyclin dependent kinase inhibiting purine derivatives
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
DK2020408T3 (da) 1998-05-29 2013-09-30 Sugen Inc Pyrrol-substitueret 2-indolinon som proteinkinaseinhibitor
US20030083242A1 (en) 1998-11-06 2003-05-01 Alphonse Galdes Methods and compositions for treating or preventing peripheral neuropathies
CN100340575C (zh) 1999-06-25 2007-10-03 杰南技术公司 人源化抗ErbB2抗体及其在制备药物中的应用
US6806266B1 (en) 1999-07-13 2004-10-19 Kyowa Hakko Kogyo Co., Ltd. Staurosporin derivatives
UA72946C2 (uk) 1999-11-05 2005-05-16 Астразенека Аб Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
DE60030770T2 (de) * 1999-12-06 2007-09-06 Rhode Island Hospital Verwendung von taurolidin oder taurultam zur herstellung eines medikaments zur behandlung von ovarialkarzinomen
CA2399358C (en) 2000-02-15 2006-03-21 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
PT1274718E (pt) 2000-04-12 2007-01-31 Genaera Corp Processo para a preparação de esteróis 7. alfa-hidroxi 3- aminosubstítuidos utilizando intermediários com um grupo 7. alfa-hidroxilo desprotegido
JP4102185B2 (ja) 2000-06-30 2008-06-18 グラクソ グループ リミテッド キナゾリンジトシル酸塩化合物
EA006711B1 (ru) 2000-09-11 2006-02-24 Чирон Корпорейшн Хинолиноновые производные в качестве ингибиторов тирозинкиназы
US6677450B2 (en) 2000-10-06 2004-01-13 Bristol-Myers Squibb Company Topoisomerase inhibitors
AU2002245272B2 (en) 2001-01-16 2006-06-29 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
WO2002062826A1 (fr) 2001-02-07 2002-08-15 Vadim Viktorovich Novikov Procede de fabrication des peptides
EP1404689A1 (en) 2001-07-02 2004-04-07 Debiopharm S.A. Oxaliplatin active substance with a very low content of oxalic acid
KR100484504B1 (ko) 2001-09-18 2005-04-20 학교법인 포항공과대학교 쿠커비투릴 유도체를 주인 분자로서 포함하고 있는 내포화합물 및 이를 포함한 약제학적 조성물
US20030134846A1 (en) 2001-10-09 2003-07-17 Schering Corporation Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
WO2003077902A1 (en) 2002-02-19 2003-09-25 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
CA2480638C (en) 2002-03-29 2013-02-12 Chiron Corporation Substituted benzazoles and use thereof as raf kinase inhibitors
US6727272B1 (en) 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
EP1587473A4 (en) 2002-12-27 2008-08-13 Novartis Vaccines & Diagnostic THIOSEMICARBAZONES ANTIVIRAL AND IMMUNOSTIMULANTS
ES2391770T3 (es) 2003-01-21 2012-11-29 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos de triptantrina para la potenciación inmune
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
SI3248600T1 (sl) * 2005-02-18 2020-09-30 Abraxis Bioscience, Llc Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
CN105412105A (zh) * 2010-11-08 2016-03-23 诺华有限公司 2-甲酰胺环氨基尿素衍生物在治疗egfr依赖性疾病或对靶向egfr家族成员的药剂有获得性耐受性的疾病中的应用
US9006270B2 (en) * 2011-06-21 2015-04-14 Novartis Ag Polymorphs of (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide
EP2601965A1 (en) * 2011-12-06 2013-06-12 Apeiron Biologics AG Compositions for preventing or treating adverse reactions of EGFR inhibition
MX360892B (es) 2012-05-16 2018-11-20 Novartis Ag Régimen de dosificación para un inhibidor de cinasa pi-3.

Also Published As

Publication number Publication date
SI3076969T1 (sl) 2021-12-31
CL2016001361A1 (es) 2017-02-10
HK1223549A1 (zh) 2017-08-04
TN2016000179A1 (en) 2017-10-06
PH12016501026A1 (en) 2016-07-04
JP2016539149A (ja) 2016-12-15
EP4000619A1 (en) 2022-05-25
CA2930359C (en) 2022-03-01
CN105979947A (zh) 2016-09-28
US20210196696A1 (en) 2021-07-01
KR20160095035A (ko) 2016-08-10
EP3076969B1 (en) 2021-09-01
IL245709A0 (en) 2016-07-31
AU2017245292A1 (en) 2017-11-02
TWI666019B (zh) 2019-07-21
IL245709B (en) 2021-03-25
US10434092B2 (en) 2019-10-08
AU2017245292B2 (en) 2018-09-27
PT3076969T (pt) 2021-11-23
TW201609096A (zh) 2016-03-16
PL3076969T3 (pl) 2022-01-17
US20170000778A1 (en) 2017-01-05
EP3076969A1 (en) 2016-10-12
US20200069670A1 (en) 2020-03-05
ES2899167T3 (es) 2022-03-10
HUE057092T2 (hu) 2022-04-28
MX2016007376A (es) 2017-05-11
WO2015083101A1 (en) 2015-06-11
AU2014358773A1 (en) 2016-06-02
RU2680246C1 (ru) 2019-02-19
BR112016011811A2 (pt) 2017-08-08
CA2930359A1 (en) 2015-06-11
US20180078540A1 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
DK3057586T3 (da) Bromodomæneinhibitorer
DK3010503T3 (da) Hidtil ukendte bicykliske bromodomæne-inhibitorer
ZA201602245B (en) Inhibitors of kras g12c
DK3080100T3 (da) Hæmmere af lysinspecifik demethylase-1
HK1212691A1 (zh) 犬尿氨酸途徑的抑制劑
DK3004166T3 (da) Fremgangsmåder til forbedring af allergen-specifik immunterapi ved administration af en il-4r-hæmmer
AR095266A1 (es) Inhibidores de bromodominios tetraciclicos
DK3527563T3 (da) Dna-pk-inhibitorer
DK3030323T3 (da) Kdm1a-inhibitorer til behandlingen af sygdom
DK3027618T3 (da) Polymorf af syk-hæmmere
DK2981526T3 (da) Naphthylureaderivater til anvendelse som kinaseinhibitorer
DK3068776T3 (da) Inhibitorer af replikation af influenzavira
DK2968214T3 (da) Hidtil ukendte analgetiske sammensætninger
DK2986611T3 (da) Bestemte proteinkinaseinhibitorer
DK2970235T3 (da) Nye inhibitorer
HK1222339A1 (zh) 金屬-β-內酰胺酶的抑制劑
EP2988738A4 (en) THERAPEUTIC APPLICATIONS OF KINASEHEMMERN
DK3079667T3 (da) Farmaceutiske doseringsformer
DK3076969T3 (da) Doseringsregime for en alfa-isoform-selektiv phosphatidylinositol-3-kinase-hæmmer
ITMI20130606A1 (it) Composti naftoeterodiazolici disostituiti
FR2997080B1 (fr) Inhibiteurs de neprilysine
TH1401003815A (th) สารยับยั้งโบรโมโดเมน
UA27116S (uk) Комплект напрямних для меблів
TH1401007328A (th) สารยับยั้งมาโครไซคลิกของไวรัส flaviviridae ไวรัส
TH1501005374A (th) สารยับยั้ง เตตระไซคลิก โบรโมโดเมน